Holen Sie sich die Stockscreener-App
72.43
0.03%
-0.02
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$72.45
Offen:
$72.4
24-Stunden-Volumen:
1.86M
Relative Volume:
0.40
Marktkapitalisierung:
$11.29B
Einnahmen:
$1.21B
Nettoeinkommen (Verlust:
$109.52M
KGV:
104.04
EPS:
0.6962
Netto-Cashflow:
$269.60M
1W Leistung:
+0.11%
1M Leistung:
+0.47%
6M Leistung:
+25.20%
1J Leistung:
+36.87%
1-Tages-Spanne:
$72.40
$72.48
1-Wochen-Bereich:
$72.14
$72.58
52-Wochen-Spanne:
$43.20
$72.62
Bio Techne Corp Stock (TECH) Company Profile
Firmenname
Bio Techne Corp
Sektor
Branche
Telefon
612-379-8854
Adresse
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
72.43 | 11.26B | 1.21B | 109.52M | 269.60M | 0.6962 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-07-22 | Fortgesetzt | Stephens | Overweight |
| 2025-07-09 | Eingeleitet | TD Cowen | Buy |
| 2025-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-09 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-08 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-02-02 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-08-28 | Eingeleitet | William Blair | Outperform |
| 2023-01-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | Hochstufung | Stifel | Hold → Buy |
| 2021-01-25 | Bestätigt | The Benchmark Company | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-07-15 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-14 | Eingeleitet | The Benchmark Company | Buy |
| 2020-01-08 | Fortgesetzt | Stephens | Overweight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-02 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-14 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | Herabstufung | Craig Hallum | Buy → Hold |
| 2018-10-17 | Eingeleitet | Goldman | Neutral |
| 2018-06-15 | Eingeleitet | Argus | Buy |
| 2017-07-13 | Eingeleitet | Wells Fargo | Market Perform |
| 2017-02-09 | Eingeleitet | Citigroup | Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-01-21 | Bestätigt | Robert W. Baird | Outperform |
| 2013-09-20 | Hochstufung | Robert W. Baird | Neutral → Outperform |
Alle ansehen
Bio Techne Corp Aktie (TECH) Neueste Nachrichten
Bio-Techne Gives FTC More Time On $11.3B Merck Deal - Law360
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation? - TradingView
Bio-Techne (Nasdaq: TECH) investors to vote on Merck cash takeover - Stock Titan
Bio-Techne (NASDAQ: TECH) GC gets new RSU grants, no stock sales - Stock Titan
Bio-Techne (NASDAQ: TECH) grants CFO 22,438 and 36,459 RSUs - Stock Titan
Bio-Techne (TECH) director granted 1,381 RSUs vesting 2027-29 - Stock Titan
Bio-Techne (TECH) insider updates stock holdings - Stock Titan
Bio-Techne (NASDAQ: TECH) grants president 8,702 and 14,140 RSUs - Stock Titan
Benchmark reiterates Hold stock rating on Bio-Techne after Q4 results - Investing.com India
BIO-TECHNE Executive Steven C. Crouse Files Form 4 After RSU Vesting and Share Withholding - Kalkine Media
Bio-Techne (TECH) CEO exercises awards, 10.8K shares withheld - Stock Titan
Bio-Techne (TECH) CFO exercises awards, covers taxes in stock - Stock Titan
Bio-Techne (NASDAQ: TECH) exec updates option and RSU holdings - Stock Titan
Bio-Techne (TECH) GC sees RSUs vest, others forfeited on equity awards - Stock Titan
Bio-Techne (TECH) awards give executive 5,423 shares, 1,947 withheld - Stock Titan
Bio-Techne (TECH) director exercises 589 RSUs, uses shares for taxes - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Is Wall Street Bullish or Bearish on Bio-Techne Stock? - Yahoo Finance
Bio-Techne (TECH) Holds Steady at $72.40 as Life Sciences Sector Digests Mixed SignalsOption Strike Build - vinanet.vn
S&CO Inc. Buys Shares of 76,614 Bio-Techne Corp $TECH - MarketBeat
TECH Q2 2026 Earnings: EPS Misses Consensus, Shares Edge HigherMargin Guidance - vinanet.vn
TECH Q2 2026 Earnings: EPS Misses Consensus by 3.34% as Shares Edge HigherSaaS Earnings Trends - vinanet.vn
Bio-Techne Corp (TECH) Stock News Today - tradingkey.com
Wells Fargo Initiates Bio-Techne(TECH.US) With Hold Rating, Announces Target Price $73 - Moomoo
Bio-Techne's Fiscal Q4 Organic Revenue Growth Consistent With Progressive Improvement Story, RBC Says - marketscreener.com
Bio-Techne (NASDAQ:TECH) Downgraded to Equal Weight Rating by Wells Fargo & Company - MarketBeat
Bio-Techne (NASDAQ:TECH) Dividend Move Sparks Fresh Attention - Kalkine Media
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises - The Globe and Mail
Bio-Techne Keeps Quarterly Dividend at $0.08 a Share, Payable Aug. 28 to Shareholders of Record as of Aug. 24 - marketscreener.com
Bio-Techne Corp (NASDAQ:TECH) to Issue Dividend Increase$0.65 Per Share - MarketBeat
Bio-Techne Dividend Payable Aug. 28 After Record-Date Correction - Stock Titan
Bio-Techne Corp to Issue Quarterly Dividend of $0.08 (NASDAQ:TECH) - MarketBeat
Bio-Techne (NASDAQ:TECH) Releases Earnings Results, Meets Estimates - MarketBeat
Bio-Techne earnings matched, revenue topped estimates - Investing.com
Bio-Techne Announces Q4 and Full Fiscal Year 2026 Financial Results Alongside Cash Dividend Declaration - Kalkine Media
Bio-Techne Q4 Results: Sales rise 1.33% YoY, beat estimates - scanx.trade
Bio-Techne Releases Fourth Quarter Fiscal 2026 Results - investingnews.com
TECH Looks 1.1% Undervalued on GF Value™ Amid High P/E and Mixed Guru Activity - GuruFocus
Techne (TECH) Q4 Earnings Meet Estimates - Yahoo Finance
Bio-Techne (NASDAQ:TECH) Surprises With Q2 CY2026 Sales - Yahoo Finance
Bio-Techne earnings matched, revenue topped estimates By Investing.com - Investing.com South Africa
Bio-Techne beats revenue estimates on research, diagnostics demand uptick - finance.yahoo.com
Bio-Techne declares $0.08 quarterly dividend - Investing.com
Form 8K Bio-Techne Corp For: 12 August By Investing.com - Investing.com Australia
Is Bio-Techne Corp (TECH) Undervalued After Q4 Earnings Beat? GA - GuruFocus
Bio-Techne reports in-line Q4 earnings, beats on revenue - Investing.com
Bio-Techne reports in-line Q4 earnings, beats on revenue By Investing.com - Investing.com India
Bio-Techne Q4 FY2026 earnings: Organic revenue grows 3% as adjusted EPS slips - TradingKey
Bio-Techne Q4 Revenue Rises to $321.2 Million - Quiver Quantitative
Bio-Techne Declares Dividend - Yahoo Finance
Bio-Techne Corp $TECH Stake Decreased by Bank of America Corp DE - MarketBeat
Finanzdaten der Bio Techne Corp-Aktie (TECH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bio Techne Corp-Aktie (TECH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hippel James | CFO |
Aug 15 '26 |
Option Exercise |
0.00 |
9,779 |
0 |
174,493 |
| Geist William | PRESIDENT, PROTEIN SCIENCES |
Aug 15 '26 |
Option Exercise |
0.00 |
6,416 |
0 |
26,919 |
| Bohnen Shane | SVP - General Counsel |
Aug 15 '26 |
Option Exercise |
0.00 |
4,350 |
0 |
11,703 |
| Crouse Steven C. | President - Diag & Spatial Bi |
Aug 15 '26 |
Option Exercise |
0.00 |
5,423 |
0 |
12,184 |
| Herr Amy E. | Director |
Aug 15 '26 |
Option Exercise |
0.00 |
589 |
0 |
789 |
| Hippel James | CFO |
Jul 29 '26 |
Option Exercise |
47.60 |
62,068 |
2,954,437 |
215,738 |
| Kelderman Kim | Chief Executive Officer |
Jul 28 '26 |
Option Exercise |
47.60 |
35,000 |
1,666,000 |
100,799 |
| Bohnen Shane | SVP - General Counsel |
Jul 23 '26 |
Option Exercise |
47.60 |
448 |
21,325 |
7,697 |
| Herr Amy E. | Director |
May 08 '26 |
Option Exercise |
47.60 |
6,636 |
315,874 |
6,836 |
| Herr Amy E. | Director |
May 08 '26 |
Sale |
48.28 |
6,636 |
320,386 |
200 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):